Akero Therapeutics Inc (AKRO)
$29.03 -$0.96 (-3.16%) 4:38 PM 12/12/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$2.17B -
Day's Range
$29.24 - $30.54 -
Volume
500,342 -
52 Week Low / High
$15.32 - $37.00 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 7
- Strong Buy
- 3
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong Sell
- $43.56
- Target Price
Company News
-
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...
-
Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...
-
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...
-
Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...
-
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...
-
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference — Sep 30th, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announce...
-
Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...
-
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference — Sep 30th, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announce...
-
Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...
-
Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...
-
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...
-
Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...
-
Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...
-
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...
-
Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...
-
Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...
-
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...
-
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...
-
Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...
-
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference — Sep 30th, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announce...
-
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...
-
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference — Sep 30th, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announce...
-
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...
-
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference — Sep 30th, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announce...
-
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference — Sep 30th, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announce...
-
Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...
-
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...
-
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference — Sep 30th, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announce...
-
Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...
-
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...
-
Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...
-
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...
-
Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...
-
Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...
-
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...
-
Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...
Similar Stocks
Portfolio
Comprised of 1 portfolios